Arrowstreet Capital Limited Partnership Buys 38,991 Shares of Masimo Corporation (MASI)
Arrowstreet Capital Limited Partnership boosted its stake in shares of Masimo Corporation (NASDAQ:MASI) by 3.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,113,113 shares of the medical equipment provider’s stock after purchasing an additional 38,991 shares during the period. Arrowstreet Capital Limited Partnership owned 2.14% of Masimo Corporation worth $101,494,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Fortaleza Asset Management Inc. acquired a new position in Masimo Corporation during the second quarter valued at approximately $106,000. Dubuque Bank & Trust Co. boosted its position in Masimo Corporation by 3.4% during the second quarter. Dubuque Bank & Trust Co. now owns 1,869 shares of the medical equipment provider’s stock valued at $170,000 after purchasing an additional 61 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Masimo Corporation by 13.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,018 shares of the medical equipment provider’s stock valued at $184,000 after purchasing an additional 236 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Masimo Corporation during the second quarter valued at approximately $203,000. Finally, Neuberger Berman Group LLC acquired a new position in Masimo Corporation during the first quarter valued at approximately $206,000. 83.21% of the stock is owned by hedge funds and other institutional investors.
MASI has been the subject of several recent research reports. BTIG Research raised Masimo Corporation from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a research report on Monday, August 14th. Stifel Nicolaus reissued a “buy” rating and set a $108.00 price target (up from $105.00) on shares of Masimo Corporation in a research report on Thursday, August 3rd. Roth Capital increased their price target on Masimo Corporation from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, July 19th. BidaskClub raised Masimo Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, July 12th. Finally, Zacks Investment Research cut Masimo Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, October 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $97.00.
Masimo Corporation (NASDAQ MASI) traded up 0.03% during mid-day trading on Friday, reaching $87.14. The company’s stock had a trading volume of 230,372 shares. The company has a market cap of $4.53 billion, a price-to-earnings ratio of 14.28 and a beta of 0.82. Masimo Corporation has a 52-week low of $53.78 and a 52-week high of $104.71. The firm has a 50 day moving average price of $85.34 and a 200 day moving average price of $90.19.
Masimo Corporation (NASDAQ:MASI) last announced its earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.12. Masimo Corporation had a return on equity of 23.45% and a net margin of 45.90%. The firm had revenue of $192.90 million for the quarter, compared to the consensus estimate of $189.03 million. During the same quarter in the previous year, the business earned $0.57 EPS. The company’s revenue was up 11.8% compared to the same quarter last year. Equities research analysts anticipate that Masimo Corporation will post $2.80 earnings per share for the current year.
WARNING: “Arrowstreet Capital Limited Partnership Buys 38,991 Shares of Masimo Corporation (MASI)” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/10/08/arrowstreet-capital-limited-partnership-buys-38991-shares-of-masimo-corporation-masi.html.
In other news, Director Sanford Fitch sold 11,000 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $87.25, for a total value of $959,750.00. Following the transaction, the director now owns 72,249 shares in the company, valued at approximately $6,303,725.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Anand Sampath sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $92.00, for a total value of $3,680,000.00. Following the completion of the transaction, the chief operating officer now owns 20,000 shares in the company, valued at approximately $1,840,000. The disclosure for this sale can be found here. Insiders sold a total of 112,000 shares of company stock worth $10,444,090 in the last 90 days. Company insiders own 16.60% of the company’s stock.
About Masimo Corporation
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Stock Ratings for Masimo Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corporation and related stocks with our FREE daily email newsletter.